Lixte Biotech to Showcase Cancer Drug LB-100 at 2026 Investor Conference
January 20, 2026 — Lixte Biotechnology announces CEO Geordan Pursglove will present LB-100, a first-in-class cancer drug, at the 2026 DealFlow Discovery Conference, highlighting clinical trials and investor engagement.